Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Transcode Therapeutics Inc RNAZ

Healthcare Biotechnology
TransCode Therapeutics, Inc., a biopharmaceutical company, focuses on developing and commercializing drugs and diagnostics for treating and identifying cancer. The company’s lead therapeutic candidate comprises TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others... see more
{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
{{currentVideo.headline}}
{{currentVideo.link1Text}}
{{currentVideo.link2Text}}
< Previous
{{moreVideoText}}
Next >

Current News (NDAQ:RNAZ)

TransCode Therapeutics and Quantum Leap Healthcare Collaborative Launch a Phase 2a dose-expansion trial with TTX-MC138, following positive readouts from TransCode's Phase 1 trial

PR Newswire December 11, 2025

TransCode Therapeutics Expands Executive Team with Appointment of Dr. Michel Janicot as Senior Development Officer

PR Newswire November 17, 2025

TransCode Therapeutics presents preliminary data from its completed Phase 1a study with TTX-MC138 in metastatic disease at ESMO

PR Newswire October 14, 2025

TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company

PR Newswire October 8, 2025

TransCode Therapeutics Appoints Dr. Phillip D. Zamore to Science Advisory Board

PR Newswire May 28, 2025

TransCode Therapeutics Successfully Completes Initial Dosing of Patients in Cohort 4 of Phase 1a Clinical Trial; No Dose Limiting Toxicities Reported

PR Newswire May 8, 2025

TransCode Therapeutics Announces Effective Date for 1-for-28 Reverse Stock Split

PR Newswire May 5, 2025

TransCode Therapeutics Announces 1-for-28 Reverse Stock Split

PR Newswire May 2, 2025

TransCode Therapeutics Reports Further Progress on Phase 1a Clinical Trial with No Dose Limiting Toxicities Reported in Patients with Metastatic Cancer

PR Newswire May 1, 2025
View More News ››

Opinion & Analysis (NDAQ:RNAZ)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:RNAZ)

Buy buddy buy.

FYI most of my stocks are for day trading purposes only and you should dydd
coolfooldumbguy - 7 days ago

RE:Buy buddy buy.

So....exactly where was this going?  Sure it popped in premarket on the news, but has been flushed back down now.   So...
FullMetals - October 8, 2025

Buy buddy buy.

Otherwise FOMO for you fellas out there today anyway,so good luck to all of you guys
coolfooldumbguy - October 8, 2025

Still holding this stock.

This is a good buy and hold position for my portfolio.Well,it is going to do well for us shareholders this year.
coolfooldumbguy - January 28, 2025

TransCode Therapeutics (NASDAQ:RNAZ): A Pioneer in RNA Oncol

Interesting play in RNA oncology. TTX-MC138 looks promising with complete metastatic regression in mouse models. FDA just gave green...
MikeTester - January 24, 2025

Buy buddy buy because it's taking off this morning.

And furthermore you guys out there will be left behind.
coolfooldumbguy - January 24, 2025
View more Bullboard ››

AJN Resources Inc.

AJN Resources Inc.

AJN Resources Inc. is a Canada-based junior exploration company and is engaged in the exploration and evaluation of mineral ...
View More »

Podcasts